Eli Lilly’s retatrutide is under investigation in another six Phase III trials.

Consider two seemingly unrelated medical puzzles. First: Every day, our bodies produce hundreds of billions of new cells, ...

Novo Nordisk has reported the first mid-stage clinical data with its triple G agonist for diabetes in China, as it starts an ...

Retatrutide is an investigational once-weekly triple hormone (glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon) receptor agonist.

No increased risk for preterm birth seen in association with periconceptional exposure to GLP-1 receptor agonists for weight loss.

GIP and glucagon (triple G), being jointly developed by United Biotechnology and Novo Nordisk In a phase 2 trial in Chinese ...

GLP receptor agonists tied to lower substance use disorder risk in veterans, reducing emergency visits, hospitalizations, and overdose incidents.

A research team at National Taiwan University found that abnormal blood flow activates CB1 receptors in endothelial cells, ...

A new study found that people with depression and anxiety who used GLP-1 drugs like Ozempic and Wegovy had a 42% lower risk ...

The use of glucagon-like peptide-1 (GLP-1) receptor agonists is associated with reduced risks for developing substance use disorders (SUDs).